Matching articles for "Issue 1282"

A Rivastigmine Patch for Dementia

   
The Medical Letter on Drugs and Therapeutics • March 24, 2008;  (Issue 1282)
Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system (Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate,...
Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system (Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate, has been approved by the FDA for treatment of mild to moderate dementia associated with Alzheimer's or Parkinson's disease. An oral formulation of rivastigmine tartrate has been available in the US since 2000,2 but gastrointestinal adverse effects possibly related to rapidly rising serum concentrations have limited its use.
Med Lett Drugs Ther. 2008 Mar 24;50(1282):21-2 | Show Full IntroductionHide Full Introduction

Palatal Implants for Snoring and Obstructive Sleep Apnea

   
The Medical Letter on Drugs and Therapeutics • March 24, 2008;  (Issue 1282)
Treatment options for snoring and obstructive sleep apnea (OSA) now include, in addition to lifestyle remedies such as weight loss and avoidance of alcohol in the evening, mechanical devices, injection of...
Treatment options for snoring and obstructive sleep apnea (OSA) now include, in addition to lifestyle remedies such as weight loss and avoidance of alcohol in the evening, mechanical devices, injection of botulinum toxin into the soft palate and a variety of ENT surgical outpatient procedures. Palatal implants (Pillar procedure - Restore Medical Inc) have been approved by the FDA for treatment of snoring and OSA.
Med Lett Drugs Ther. 2008 Mar 24;50(1282):23-4 | Show Full IntroductionHide Full Introduction

In Brief: Influenza Developments

   
The Medical Letter on Drugs and Therapeutics • March 24, 2008;  (Issue 1282)
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81), the influenza B and A/H3N2 antigens, do not...
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81), the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir (Tamiflu), particularly in Europe; in the US and Canada, about 5% of influenza A/H1N1 isolates are resistant to oseltamivir in vitro.

Download U.S. English
Med Lett Drugs Ther. 2008 Mar 24;50(1282):21-4 | Show Full IntroductionHide Full Introduction